

Michael J Pencina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3338088/publications.pdf>

Version: 2024-02-01

199
papers

46,200
citations

7672

79
h-index

3037

194
g-index

201
all docs

201
docs citations

201
times ranked

59165
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Impact of Hybrid Comprehensive Telerehabilitation Regarding Diastolic Dysfunction in Patients with Heart Failure with Reduced Ejection Fraction—Subanalysis of the TELEREH-HF Randomized Clinical Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 1844.	1.0	0
2	A framework for the oversight and local deployment of safe and high-quality prediction models. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 29, 1631-1636.	2.2	23
3	Clinical Trials in the 21st Century — Promising Avenues for Better Studies. , 2022, 1, .		3
4	Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care. <i>American Heart Journal</i> , 2021, 231, 1-5.	1.2	73
5	The Dose—Response Relationship Between Physical Activity and Cardiometabolic Health in Adolescents. <i>American Journal of Preventive Medicine</i> , 2021, 60, 95-103.	1.6	17
6	An aetiology—based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH—HF) trial. <i>ESC Heart Failure</i> , 2021, 8, 1263-1273.	1.4	7
7	Effects of hybrid comprehensive telerehabilitation on cardiopulmonary capacity in heart failure patients depending on diabetes mellitus: subanalysis of the TELEREH-HF randomized clinical trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 106.	2.7	10
8	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1981-1990.	13.9	145
9	Antiarrhythmic effect of 9-week hybrid comprehensive telerehabilitation and its influence on cardiovascular mortality in long-term follow-up — subanalysis of the TELEREH—HF randomized clinical trial. <i>Archives of Medical Science</i> , 2021, 18, 293-306.	0.4	0
10	Incremental Benefits of Machine Learning—When Do We Need a Better Mousetrap?. <i>JAMA Cardiology</i> , 2021, 6, 621.	3.0	15
11	Assessment of ECG during hybrid comprehensive telerehabilitation in heart failure patients—Subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH—HF) randomized clinical trial. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12887.	0.5	5
12	Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 300.	3.0	104
13	Remote Monitoring of Cardiac Implantable Electronic Devices in Patients Undergoing Hybrid Comprehensive Telerehabilitation in Comparison to the Usual Care. Subanalysis from Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomised Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3729.	1.0	8
14	The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. <i>Circulation</i> , 2020, 142, 827-837.	1.6	44
15	Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). <i>JAMA Cardiology</i> , 2020, 5, 988.	3.0	16
16	Prediction Models — Development, Evaluation, and Clinical Application. <i>New England Journal of Medicine</i> , 2020, 382, 1583-1586.	13.9	77
17	Application of net reclassification index to non-nested and point-based risk prediction models: a review. <i>European Heart Journal</i> , 2019, 40, 1880-1887.	1.0	39
18	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. <i>JAMA Neurology</i> , 2019, 76, 1192.	4.5	70

#	ARTICLE	IF	CITATIONS
19	Trajectories of Non-HDL Cholesterol Across Midlife. <i>Journal of the American College of Cardiology</i> , 2019, 74, 70-79.	1.2	67
20	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019, 218, 110-122.	1.2	7
21	Statistical methods for building better biomarkers of chronic kidney disease. <i>Statistics in Medicine</i> , 2019, 38, 1903-1917.	0.8	7
22	Measures for evaluation of prognostic improvement under multivariate normality for nested and nonnested models. <i>Statistics in Medicine</i> , 2019, 38, 3817-3831.	0.8	6
23	Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research. <i>JAMA Cardiology</i> , 2019, 4, 375.	3.0	43
24	Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country. <i>American Heart Journal</i> , 2019, 218, 32-45.	1.2	1
25	Single-number summary and decision analytic measures can happily coexist. <i>Statistics in Medicine</i> , 2019, 38, 499-500.	0.8	1
26	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. <i>Circulation</i> , 2019, 139, 1603-1611.	1.6	115
27	Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 579-590.	3.0	114
28	Microsimulation model to predict incremental value of biomarkers added to prognostic models. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 1382-1385.	2.2	2
29	Deriving Real-World Insights From Real-World Data: Biostatistics to the Rescue. <i>Annals of Internal Medicine</i> , 2018, 169, 401.	2.0	9
30	Rejoinder. <i>Clinical Trials</i> , 2017, 14, 126-127.	0.7	0
31	Data monitoring committees: Promoting best practices to address emerging challenges. <i>Clinical Trials</i> , 2017, 14, 115-123.	0.7	61
32	Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1057.	3.8	179
33	Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 169-176.	0.3	9
34	Transcatheter Versus Surgical Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2017, 70, 439-450.	1.2	82
35	Authors' response to comments. <i>Statistics in Medicine</i> , 2017, 36, 4511-4513.	0.8	3
36	Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2017, 136, 1860-1862.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Asymptotic distribution of $\hat{\tau}$ AUC, NRIs, and IDI based on theory of U-statistics. <i>Statistics in Medicine</i> , 2017, 36, 3334-3360.	0.8	20
38	Discrimination slope and integrated discrimination improvement $\hat{\alpha}$ properties, relationships and impact of calibration. <i>Statistics in Medicine</i> , 2017, 36, 4482-4490.	0.8	37
39	Net reclassification index at event rate: properties and relationships. <i>Statistics in Medicine</i> , 2017, 36, 4455-4467.	0.8	70
40	Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. <i>JAMA Cardiology</i> , 2016, 1, 700.	3.0	13
41	Estimation of Risk for Initial Atherosclerotic Cardiovascular Disease Events. <i>Circulation</i> , 2016, 134, 1792-1793.	1.6	1
42	A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study. <i>BMC Medical Research Methodology</i> , 2016, 16, 148.	1.4	50
43	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 126.	3.0	196
44	Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment. <i>JAMA Cardiology</i> , 2016, 1, 864.	3.0	29
45	Risk Prediction With Electronic Health Records. <i>JAMA Cardiology</i> , 2016, 1, 976.	3.0	25
46	Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates. <i>Journal of Pediatrics</i> , 2016, 178, 125-129.e1.	0.9	27
47	Open Access Platforms for Sharing Clinical Trial Data—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 666.	3.8	1
48	Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2041.	3.8	30
49	A calibration hierarchy for risk models was defined: from utopia to empirical data. <i>Journal of Clinical Epidemiology</i> , 2016, 74, 167-176.	2.4	473
50	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCCEL) trial. <i>American Heart Journal</i> , 2016, 174, 103-110.	1.2	82
51	Use of Open Access Platforms for Clinical Trial Data. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1283.	3.8	57
52	Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute—Bristol-Myers Squibb Supporting Open Access to Researchers Initiative. <i>American Heart Journal</i> , 2016, 172, 64-69.	1.2	28
53	Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2016, 133, 1574-1581.	1.6	66
54	Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives. <i>Biometrical Journal</i> , 2015, 57, 556-570.	0.6	21

#	ARTICLE	IF	CITATIONS
55	Response to Letter Regarding Article, "Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease." <i>Circulation</i> , 2015, 132, e203.	1.6	2
56	Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1321-1327.	0.8	112
57	Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. <i>Circulation</i> , 2015, 131, 451-458.	1.6	283
58	Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. <i>Circulation</i> , 2015, 132, 1404-1413.	1.6	43
59	The Role of Physicians in the Era of Predictive Analytics. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 25.	3.8	55
60	Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1633-1639.	1.2	58
61	P-wave indices and atrial fibrillation: Cross-cohort assessments from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) study. <i>American Heart Journal</i> , 2015, 169, 53-61.e1.	1.2	74
62	RE: Net Risk Reclassification P Values: Valid or Misleading?. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju355-dju355.	3.0	8
63	Application of New Cholesterol Guidelines to a Population-Based Sample. <i>New England Journal of Medicine</i> , 2014, 370, 1422-1431.	13.9	571
64	Net reclassification improvement and integrated discrimination improvement require calibrated models: relevance from a marker and model perspective. <i>Statistics in Medicine</i> , 2014, 33, 3415-3418.	0.8	47
65	Heparin Monotherapy or Bivalirudin During Percutaneous Coronary Intervention in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes or Stable Ischemic Heart Disease. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 365-373.	1.4	13
66	Left Ventricular Hypertrophy Patterns and Incidence of Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2014, 113, 117-122.	0.7	103
67	Charting a Roadmap for Heart Failure Biomarker Studies. <i>JACC: Heart Failure</i> , 2014, 2, 477-488.	1.9	81
68	Net Reclassification Improvement: Computation, Interpretation, and Controversies. <i>Annals of Internal Medicine</i> , 2014, 160, 122-131.	2.0	453
69	What to expect from net reclassification improvement with three categories. <i>Statistics in Medicine</i> , 2014, 33, 4975-4987.	0.8	20
70	Understanding increments in model performance metrics. <i>Lifetime Data Analysis</i> , 2013, 19, 202-218.	0.4	32
71	Association of Smoking Cessation and Weight Change With Cardiovascular Disease Among Adults With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1014.	3.8	216
72	Impact of correlation on predictive ability of biomarkers. <i>Statistics in Medicine</i> , 2013, 32, 4196-4210.	0.8	17

#	ARTICLE	IF	CITATIONS
73	Risk assessment for incident heart failure in individuals with atrial fibrillation. <i>European Journal of Heart Failure</i> , 2013, 15, 843-849.	2.9	96
74	Prostate-specific Antigen Velocity: New Methods, Same Results, Still No Evidence of Clinical Utility. <i>European Urology</i> , 2013, 64, 394-396.	0.9	6
75	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	3.1	90
76	Genetic Predisposition to Higher Blood Pressure Increases Coronary Artery Disease Risk. <i>Hypertension</i> , 2013, 61, 995-1001.	1.3	70
77	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	0.9	36
78	Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE—AF Consortium. <i>Journal of the American Heart Association</i> , 2013, 2, e000102.	1.6	601
79	Neck Circumference and the Development of Cardiovascular Disease Risk Factors in the Framingham Heart Study. <i>Diabetes Care</i> , 2013, 36, e3-e3.	4.3	53
80	Atrial Fibrillation Patterns and Risks of Subsequent Stroke, Heart Failure, or Death in the Community. <i>Journal of the American Heart Association</i> , 2013, 2, e000126.	1.6	61
81	Validation of a Breast Cancer Risk Prediction Model Developed for Black Women. <i>Journal of the National Cancer Institute</i> , 2013, 105, 361-367.	3.0	13
82	Age Trends in Estradiol and Estrone Levels Measured Using Liquid Chromatography Tandem Mass Spectrometry in Community-Dwelling Men of the Framingham Heart Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013, 68, 733-740.	1.7	71
83	Evaluation of Markers and Risk Prediction Models. <i>Medical Decision Making</i> , 2013, 33, 490-501.	1.2	71
84	Early-Adulthood Cardiovascular Disease Risk Factor Profiles Among Individuals With and Without Diabetes in the Framingham Heart Study. <i>Diabetes Care</i> , 2013, 36, 1590-1596.	4.3	25
85	Lack of interaction of beta-cell-function-associated variants with hypertension on change in fasting glucose and diabetes risk. <i>Journal of Hypertension</i> , 2013, 31, 1001-1009.	0.3	0
86	Repeat Revascularization After Contemporary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 772-782.	1.4	61
87	Invited Commentary: Clinical Usefulness of the Framingham Cardiovascular Risk Profile Beyond Its Statistical Performance. <i>American Journal of Epidemiology</i> , 2012, 176, 187-189.	1.6	10
88	Comparison of Academic and Nonacademic Sites in Multi-Center Clinical Trials. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 65-68.	0.7	5
89	Genotype Prediction of Adult Type 2 Diabetes From Adolescence in a Multiracial Population. <i>Pediatrics</i> , 2012, 130, e1235-e1242.	1.0	42
90	Interpreting Incremental Value of Markers Added to Risk Prediction Models. <i>American Journal of Epidemiology</i> , 2012, 176, 473-481.	1.6	397

#	ARTICLE	IF	CITATIONS
91	Evaluating Treatment Efficacy by Multiple End Points in Phase II Acute Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2012, 5, 742-749.	1.6	42
92	Coronary Computed Tomographic Angiography and Risk of All-Cause Mortality and Nonfatal Myocardial Infarction in Subjects Without Chest Pain Syndrome From the CONFIRM Registry (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry). <i>Circulation</i> , 2012, 126, 304-313.	1.6	202
93	Thoroughly Modern Risk Prediction?. <i>Science Translational Medicine</i> , 2012, 4, 131fs10.	5.8	13
94	Pencina et al. Respond to "The Incremental Value of New Markers" and "Clinically Relevant Measures? A Note of Caution". <i>American Journal of Epidemiology</i> , 2012, 176, 492-494.	1.6	5
95	Caution Is Needed in the Interpretation of Added Value of Biomarkers Analyzed in Matched Case Control Studies. <i>Clinical Chemistry</i> , 2012, 58, 1176-1178.	1.5	8
96	Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. <i>European Heart Journal</i> , 2012, 33, 1095-1104.	1.0	88
97	Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. <i>European Heart Journal</i> , 2012, 33, 1734-1741.	1.0	122
98	Ankle-brachial index and cardiovascular risk prediction: An analysis of 11,594 individuals with 10-year follow-up. <i>Atherosclerosis</i> , 2012, 220, 160-167.	0.4	60
99	A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. <i>Atherosclerosis</i> , 2012, 223, 421-426.	0.4	69
100	Measuring Carotid Artery Intima-Media Thickness: Simplicity Versus Complexity?. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 101-104.	1.2	6
101	Variations in Common Carotid Artery Intima-Media Thickness during the Cardiac Cycle: Implications for Cardiovascular Risk Assessment. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 1023-1028.	1.2	20
102	An International Model to Predict Recurrent Cardiovascular Disease. <i>American Journal of Medicine</i> , 2012, 125, 695-703.e1.	0.6	184
103	Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1249-1256.	1.2	496
104	A Genetic Risk Score Is Associated With Incident Cardiovascular Disease and Coronary Artery Calcium. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 113-121.	5.1	196
105	Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models. <i>Statistics in Medicine</i> , 2012, 31, 101-113.	0.8	250
106	Quantifying discrimination of Framingham risk functions with different survival C statistics. <i>Statistics in Medicine</i> , 2012, 31, 1543-1553.	0.8	76
107	Misuse of DeLong test to compare AUCs for nested models. <i>Statistics in Medicine</i> , 2012, 31, 2577-2587.	0.8	192
108	Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. <i>European Journal of Clinical Investigation</i> , 2012, 42, 216-228.	1.7	165

#	ARTICLE	IF	CITATIONS
109	Parental Intermittent Claudication as Risk Factor for Claudication in Adults. American Journal of Cardiology, 2012, 109, 736-741.	0.7	12
110	Efficacy of Dose Increase Among Nonresponders to Low-Dose Aripiprazole Augmentation in Patients With Inadequate Response to Antidepressant Treatment. Journal of Clinical Psychiatry, 2012, 73, 353-357.	1.1	17
111	Rationale and design of the CONFIRM (COronary CT Angiography Evaluation N For Clinical Outcomes: An) Tj ETQq1 1 0,784314 rgBT /C 152	0.7	152
112	Strengthening the reporting of Genetic Risk Prediction Studies (GRIPS): explanation and elaboration. Journal of Clinical Epidemiology, 2011, 64, e1-e22.	2.4	9
113	Segment-Specific Association Between Plasma Homocysteine Level and Carotid Artery Intima-Media Thickness in the Framingham Offspring Study. Journal of Stroke and Cerebrovascular Diseases, 2011, 20, 155-161.	0.7	20
114	Prevalence of low ankle-brachial index, elevated plasma fibrinogen and CRP across Framingham risk categories: Data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Atherosclerosis, 2011, 216, 174-179.	0.4	14
115	Performance of current guidelines for coronary heart disease prevention: Optimal use of the Framingham-based risk assessment. Atherosclerosis, 2011, 216, 452-457.	0.4	29
116	Circulating plasma cholesteryl ester transfer protein activity and blood pressure tracking in the community. Journal of Hypertension, 2011, 29, 863-868.	0.3	5
117	Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Clinical Investigation, 2011, 41, 1010-1035.	1.7	30
118	Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Human Genetics, 2011, 19, 615-615.	1.4	12
119	Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Epidemiology, 2011, 26, 313-337.	2.5	14
120	Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Statistics in Medicine, 2011, 30, 11-21.	0.8	1,989
121	On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Statistics in Medicine, 2011, 30, 1105-1117.	0.8	972
122	Equivalence of improvement in area under ROC curve and linear discriminant analysis coefficient under assumption of normality. Statistics in Medicine, 2011, 30, 1410-1418.	0.8	29
123	Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2011, 4, 463-473.	1.4	25
124	Higher aldosterone and lower N-terminal proatrial natriuretic peptide as biomarkers of salt sensitivity in the community. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 664-673.	3.1	12
125	Improved Cardiac Risk Assessment With Noninvasive Measures of Coronary Flow Reserve. Circulation, 2011, 124, 2215-2224.	1.6	710
126	Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2011, 306, 2221-8.	3.8	313

#	ARTICLE	IF	CITATIONS
127	Common Carotid Artery Intima-Media Thickness Progression as a Predictor of Stroke in Multi-Ethnic Study of Atherosclerosis. <i>Stroke</i> , 2011, 42, 3017-3021.	1.0	149
128	Associations of Edge-Detected and Manual-Traced Common Carotid Intima-Media Thickness Measurements With Framingham Risk Factors. <i>Stroke</i> , 2011, 42, 1912-1916.	1.0	48
129	Genetic Risk Reclassification for Type 2 Diabetes by Age Below or Above 50 Years Using 40 Type 2 Diabetes Risk Single Nucleotide Polymorphisms. <i>Diabetes Care</i> , 2011, 34, 121-125.	4.3	165
130	Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use. <i>Circulation</i> , 2011, 124, 1028-1037.	1.6	41
131	Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 474-480.	1.4	45
132	Carotid-Wall Intima-Media Thickness and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2011, 365, 213-221.	13.9	678
133	Reclassification Calculations for Persons With Incomplete Follow-up. <i>Annals of Internal Medicine</i> , 2010, 152, 195.	2.0	77
134	Cross-Sectional Relations of Lipid Concentrations to Left Ventricular Structural Attributes. <i>American Journal of Cardiology</i> , 2010, 105, 1297-1299.	0.7	5
135	Frequency of Major Noncardiac Surgery and Subsequent Adverse Events in the Year After Drug-Eluting Stent Placement. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 920-927.	1.1	141
136	An Obesity Dietary Quality Index Predicts Abdominal Obesity in Women: Potential Opportunity for New Prevention and Treatment Paradigms. <i>Journal of Obesity</i> , 2010, 2010, 1-9.	1.1	12
137	Assessing the Performance of Prediction Models. <i>Epidemiology</i> , 2010, 21, 128-138.	1.2	3,387
138	Familial Aggregation of Left Ventricular Geometry and Association With Parental Heart Failure. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 492-498.	5.1	19
139	Arterial Stiffness and Cardiovascular Events. <i>Circulation</i> , 2010, 121, 505-511.	1.6	1,824
140	Association Between Familial Atrial Fibrillation and Risk of New-Onset Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2263.	3.8	257
141	Diet Quality, Physical Activity, Smoking Status, and Weight Fluctuation Are Associated with Weight Change in Women and Men. <i>Journal of Nutrition</i> , 2010, 140, 1287-1293.	1.3	51
142	Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 327-334.	1.4	76
143	Relations of Biomarkers of Distinct Pathophysiological Pathways and Atrial Fibrillation Incidence in the Community. <i>Circulation</i> , 2010, 121, 200-207.	1.6	243
144	Validation of an Atrial Fibrillation Risk Algorithm in Whites and African Americans. <i>Archives of Internal Medicine</i> , 2010, 170, 1909-17.	4.3	120

#	ARTICLE	IF	CITATIONS
145	Free Testosterone Levels Are Associated with Mobility Limitation and Physical Performance in Community-Dwelling Men: The Framingham Offspring Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2790-2799.	1.8	130
146	Statistical methods for assessment of added usefulness of new biomarkers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1703-1711.	1.4	287
147	Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study. <i>Circulation</i> , 2009, 120, 212-220.	1.6	223
148	Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community. <i>Circulation</i> , 2009, 119, 1101-1107.	1.6	58
149	Association of Parental Obesity With Concentrations of Select Systemic Biomarkers in Nonobese Offspring. <i>Diabetes</i> , 2009, 58, 134-137.	0.3	29
150	Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005. <i>Circulation</i> , 2009, 119, 1728-1735.	1.6	507
151	Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 49.	3.8	474
152	Longitudinal Tracking of Left Ventricular Mass Over the Adult Life Course. <i>Circulation</i> , 2009, 119, 3085-3092.	1.6	168
153	Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community. <i>Circulation</i> , 2009, 120, 2414-2420.	1.6	121
154	Response to "Net reclassification improvement and decision theory" by Vickers <i>et al</i> .. <i>Statistics in Medicine</i> , 2009, 28, 526-528.	0.8	3
155	Prevalence, Clinical Correlates, and Prognosis of Discrete Upper Septal Thickening on Echocardiography: The Framingham Heart Study. <i>Echocardiography</i> , 2009, 26, 247-253.	0.3	65
156	In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 37-45.	1.1	139
157	Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. <i>Lancet</i> , The, 2009, 373, 739-745.	6.3	883
158	Predicting the 30-Year Risk of Cardiovascular Disease. <i>Circulation</i> , 2009, 119, 3078-3084.	1.6	688
159	Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. <i>Journal of Hypertension</i> , 2009, 27, 1317-1324.	0.3	10
160	Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. <i>Statistics in Medicine</i> , 2008, 27, 157-172.	0.8	5,331
161	Comments on "Integrated discrimination and net reclassification improvements" Practical advice. <i>Statistics in Medicine</i> , 2008, 27, 207-212.	0.8	1,299
162	BMI vs. Waist Circumference for Identifying Vascular Risk. <i>Obesity</i> , 2008, 16, 463-469.	1.5	65

#	ARTICLE	IF	CITATIONS
163	Performance of a Method for Identifying the Unique Dietary Patterns of Adult Women and Men: The Framingham Nutrition Studies. <i>Journal of the American Dietetic Association</i> , 2008, 108, 1453-1460.	1.3	10
164	Association of Parental Hypertension With Concentrations of Select Biomarkers in Nonhypertensive Offspring. <i>Hypertension</i> , 2008, 52, 381-386.	1.3	21
165	Impact of Impaired Fasting Glucose on Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2008, 51, 264-270.	1.2	248
166	A Risk Score for Predicting Near-Term Incidence of Hypertension: The Framingham Heart Study. <i>Annals of Internal Medicine</i> , 2008, 148, 102.	2.0	240
167	General Cardiovascular Risk Profile for Use in Primary Care. <i>Circulation</i> , 2008, 117, 743-753.	1.6	5,601
168	Aortic Root Diameter and Longitudinal Blood Pressure Tracking. <i>Hypertension</i> , 2008, 52, 473-477.	1.3	16
169	Embolic Protection and Platelet Inhibition During Renal Artery Stenting. <i>Circulation</i> , 2008, 117, 2752-2760.	1.6	163
170	Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction. <i>Circulation</i> , 2008, 118, 2057-2062.	1.6	428
171	Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study. <i>Diabetes Care</i> , 2008, 31, 1582-1584.	4.3	184
172	Relations of Thyroid Function to Body Weight_{title}Cross-sectional and Longitudinal Observations in a Community-Based Sample_{title}. <i>Archives of Internal Medicine</i> , 2008, 168, 587.	4.3	249
173	Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancerâ€œNorfolk Cohortâ€Invited Commentary. <i>Archives of Internal Medicine</i> , 2008, 168, 1216.	4.3	8
174	Vitamin D Deficiency and Risk of Cardiovascular Disease. <i>Circulation</i> , 2008, 117, 503-511.	1.6	2,077
175	Advance Care Planning and Health Care Preferences of Community-Dwelling Elders: The Framingham Heart Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2008, 63, 951-959.	1.7	42
176	Interindividual variation in serum sodium and longitudinal blood pressure tracking in the Framingham Heart Study. <i>Journal of Hypertension</i> , 2008, 26, 2121-2125.	0.3	23
177	Temporal Trends in Self-Reported Functional Limitations and Physical Disability Among the Community-Dwelling Elderly Population: The Framingham Heart Study. <i>American Journal of Public Health</i> , 2008, 98, 1256-1262.	1.5	41
178	One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1197.	3.8	1,162
179	Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors. <i>Circulation</i> , 2007, 116, 984-992.	1.6	185
180	Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus. <i>Circulation</i> , 2007, 115, 1544-1550.	1.6	567

#	ARTICLE	IF	CITATIONS
181	Algorithms for Assessing Cardiovascular Risk in Women. JAMA - Journal of the American Medical Association, 2007, 298, 173.	3.8	6
182	Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women. JAMA - Journal of the American Medical Association, 2007, 298, 776.	3.8	496
183	Characteristics of Framingham Offspring Participants With Long-lived Parents. Archives of Internal Medicine, 2007, 167, 438.	4.3	55
184	Increasing Trends in Incidence of Overweight and Obesity over 5 Decades. American Journal of Medicine, 2007, 120, 242-250.e2.	0.6	168
185	Lifetime Risk for Developing Dyslipidemia: The Framingham Offspring Study. American Journal of Medicine, 2007, 120, 623-630.e1.	0.6	14
186	LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. Journal of Clinical Lipidology, 2007, 1, 583-592.	0.6	365
187	Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study. BMC Medical Genetics, 2007, 8, S13.	2.1	171
188	Choice of time scale and its effect on significance of predictors in longitudinal studies. Statistics in Medicine, 2007, 26, 1343-1359.	0.8	147
189	Endogenous Sex Hormones and Cardiovascular Disease Incidence in Men. Annals of Internal Medicine, 2006, 145, 176.	2.0	188
190	Association of Parental Heart Failure with Risk of Heart Failure in Offspring. New England Journal of Medicine, 2006, 355, 138-147.	13.9	166
191	Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s. Circulation, 2006, 113, 2914-2918.	1.6	340
192	Estimating Lifetime Risk of Developing High Serum Total Cholesterol: Adjustment for Baseline Prevalence and Single-Occasion Measurements. American Journal of Epidemiology, 2006, 165, 464-472.	1.6	11
193	Electrocardiographic QRS Duration and the Risk of Congestive Heart Failure. Hypertension, 2006, 47, 861-867.	1.3	101
194	Estimated Risks for Developing Obesity in the Framingham Heart Study. Annals of Internal Medicine, 2005, 143, 473.	2.0	131
195	Cardiovascular Risk Factors Predictive for Survival and Morbidity-Free Survival in the Oldest-Old Framingham Heart Study Participants. Journal of the American Geriatrics Society, 2005, 53, 1944-1950.	1.3	122
196	Sibling Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-aged Adults. JAMA - Journal of the American Medical Association, 2005, 294, 3117.	3.8	213
197	Relations of Insulin Sensitivity to Longitudinal Blood Pressure Tracking. Circulation, 2005, 112, 1719-1727.	1.6	48
198	Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Statistics in Medicine, 2004, 23, 2109-2123.	0.8	1,264

#	ARTICLE	IF	CITATIONS
199	Cross-sectional relations of urinary sodium excretion to cardiac structure and hypertrophy. The Framingham Heart Study. American Journal of Hypertension, 2004, 17, 891-896.	1.0	14